Cubist Systematic Strategies LLC Sells 12,278 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Cubist Systematic Strategies LLC lowered its position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 30.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,371 shares of the company’s stock after selling 12,278 shares during the period. Cubist Systematic Strategies LLC’s holdings in Werewolf Therapeutics were worth $69,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $10,922,000. Millennium Management LLC lifted its holdings in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after purchasing an additional 544,881 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 119.8% in the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after purchasing an additional 94,212 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after purchasing an additional 233,909 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after purchasing an additional 86,800 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $2.06 on Thursday. The business’s fifty day simple moving average is $2.10 and its 200 day simple moving average is $3.38. The firm has a market capitalization of $89.52 million, a P/E ratio of -1.89 and a beta of 0.45. Werewolf Therapeutics, Inc. has a 12 month low of $1.57 and a 12 month high of $8.19. The company has a current ratio of 12.13, a quick ratio of 12.13 and a debt-to-equity ratio of 0.24.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. As a group, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

HOWL has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd. JMP Securities reiterated a “market outperform” rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday, June 26th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.